Alzheimer’s disease (AD) is a stealthy and progressive neurological disorder that is a leading cause of dementia in the global elderly population, imposing a significant burden on both the elderly and society. Currently, the condition is treated with medications that alleviate symptoms. Nonetheless, these drugs may not consistently produce the desired results and can cause serious side effects. Hence, there is a vigorous pursuit of alternative options to enhance the quality of life for patients. Ginkgo biloba (GB), an herb with historical use in traditional medicine, contains bioactive compounds such as terpenoids (Ginkgolides A, B, and C), polyphenols, organic acids, and flavonoids (quercetin, kaempferol, and isorhamnetin). These compounds are associated with anti-inflammatory, antioxidant, and neuroprotective properties, making them valuable for cognitive health. A systematic search across three databases using specific keywords—GB in AD and dementia—yielded 1702 documents, leading to the selection of 15 clinical trials for synthesis. In eleven studies, GB extract/EGb 761^® was shown to improve cognitive function, neuropsychiatric symptoms, and functional abilities in both dementia types. In four studies, however, there were no significant differences between the GB-treated and placebo groups. Significant improvements were observed in scores obtained from the Mini-Mental State Examination (MMSE), Short Cognitive Performance Test (SKT), and Neuropsychiatric Inventory (NPI). While the majority of synthesized clinical trials show that Ginkgo biloba has promising potential for the treatment of these conditions, more research is needed to determine optimal dosages, effective delivery methods, and appropriate pharmaceutical formulations. Furthermore, a thorough assessment of adverse effects, exploration of long-term use implications, and investigation into potential drug interactions are critical aspects that must be carefully evaluated in future studies.

Alzheimer's disease (AD) is a stealthy and progressive neurological disorder that is a leading cause of dementia in the global elderly population, imposing a significant burden on both the elderly and society. Currently, the condition is treated with medications that alleviate symptoms. Nonetheless, these drugs may not consistently produce the desired results and can cause serious side effects. Hence, there is a vigorous pursuit of alternative options to enhance the quality of life for patients. Ginkgo biloba (GB), an herb with historical use in traditional medicine, contains bioactive compounds such as terpenoids (Ginkgolides A, B, and C), polyphenols, organic acids, and flavonoids (quercetin, kaempferol, and isorhamnetin). These compounds are associated with anti-inflammatory, antioxidant, and neuroprotective properties, making them valuable for cognitive health. A systematic search across three databases using specific keywords GB in AD and dementia yielded 1702 documents, leading to the selection of 15 clinical trials for synthesis. In eleven studies, GB extract/EGb 761® was shown to improve cognitive function, neuropsychiatric symptoms, and functional abilities in both dementia types. In four studies, however, there were no significant differences between the GB-treated and placebo groups. Significant improvements were observed in scores obtained from the Mini-Mental State Examination (MMSE), Short Cognitive Performance Test (SKT), and Neuropsychiatric Inventory (NPI). While the majority of synthesized clinical trials show Ginkgo biloba has promising potential in these conditions, more research is needed to determine optimal dosages, effective delivery methods, and appropriate pharmaceutical formulations. Furthermore, a thorough assessment of adverse effects, exploration of long-term use implications, and investigation into potential drug interactions are critical aspects that must be carefully evaluated in future studies.

Introdução: A Doença Inflamatória Intestinal (DII), que compreende a Doença de Crohn e a Retocolite Ulcerativa, é uma condição crônica imunomediada do trato gastrointestinal, cujos impactos extrapolam o domínio físico, afetando significativamente a saúde mental e a qualidade de vida dos pacientes. Objetivo: Analisar os impactos psicossociais da DII e sua repercussão na qualidade de vida dos indivíduos acometidos, à luz das evidências científicas disponíveis. Método: Trata-se de uma Revisão Integrativa da Literatura, realizada nas bases SciELO, LILACS, Web of Science e MEDLINE. A estratégia PICo orientou a formulação da pergunta de pesquisa. Foram incluídos estudos publicados entre 2020 e 2025, em português, inglês e espanhol, que abordassem os aspectos psicossociais da DII e sua relação com a qualidade de vida. Após triagem sistematizada, 16 artigos compuseram a amostra final. A análise seguiu os critérios metodológicos de Ganong e as diretrizes PRISMA. Resultados e Discussão: A síntese dos estudos revelou alta prevalência de sintomas de ansiedade, depressão, estresse e insatisfação com a autoimagem em pacientes com DII. Destacaram-se ainda sentimentos de estigmatização, isolamento social, dificuldades em relações interpessoais e comprometimento funcional. O suporte psicossocial e as redes de apoio mostraram-se fundamentais para o enfrentamento da doença e para a adesão terapêutica. As intervenções psicossociais e o acolhimento multiprofissional foram apontados como estratégias promissoras para a promoção do bem-estar e da qualidade de vida. Considerações Finais: Os achados evidenciam a necessidade de abordagens ampliadas e interdisciplinares no cuidado às pessoas com DII. A atenção integral, que inclua aspectos emocionais e sociais, é essencial para o enfrentamento efetivo da doença, a promoção da autonomia e a melhoria dos desfechos em saúde.